Skip to content
Wednesday, August 26, 2026
1 WOMEN'S HEALTHWOMEN'S & REPRODUCTIVE HEALTH

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.

Records
5,000
Last changed
Update schedule
55 1 * * * UTC
Coverage
05/26/2000–08/25/2026
Method
Methodology
Title
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
Record Date
08/01/2024
Vuga Group
INTERVENTIONAL
Change Status
unchanged
Recency Days
755.85
Public Significance Score
0